EUDA EUDA Health
- 2.340
- +0.020+0.86%
EUDA Health News
20-F: Registration statement / Annual report / Transition report
EUDA Health Holdings Limited completed the acquisition of CK Health Plus Sdn Bhd and entered the direct sales field of comprehensive health products in Southeast Asia
SINGAPORE, May 9, 2024/PRNewswire/ -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a health technology company headquartered in Singapore that operates Southeast Asia's first digital healthcare system, is pleased to announce today that it has successfully completed the acquisition of CK Health Plus Sdn Bhd (“CK Health”). This strategic move marks the expansion of EUDA's business in Malaysia and highlights its commitment to promoting healthcare in the region
EUDA Health Expands Wellness Reach in Southeast Asia
EUDA Health Holdings Limited Completes Acquisition Of CK Health Plus Sdn Bhd, Expanding Into Direct Selling Holistic Wellness Products In Southeast Asia >EUDA
EUDA Health Holdings Limited Completes Acquisition Of CK Health Plus Sdn Bhd, Expanding Into Direct Selling Holistic Wellness Products In Southeast Asia >EUDA
Euda Health Holdings Expands Portfolio With Fortress Cove Acquisition
6-K: Report of foreign private issuer (related to financial reporting)
EUDA Health acquires CK Health and enters the field of direct sales of comprehensive health products
SINGAPORE, May 7, 2024/PRNewswire/ -- EUDA Health Holdings Limited (“EUDA” or the “Company”) (NASDAQ: EUDA), a health technology company headquartered in Singapore that operates Southeast Asia's first digital healthcare system, today announced that it will acquire CK Health Plus Sdn Bhd (“CK Health”), a direct seller of comprehensive health consumer products in Malaysia. Under the terms of the acquisition agreement, EUDA agreed to adopt the company's new 1,000
EUDA Health Holdings Acquires CK Health For Aggregate Share Consideration Of 10M Newly Issued Ordinary Shares Valued At $15M
EUDA Health Holdings Acquires CK Health For Aggregate Share Consideration Of 10M Newly Issued Ordinary Shares Valued At $15M
EUDA Health Holdings to Issue 10M Ordinary Shrs Valued at $15M to Purchase CK Health >EUDA
EUDA Health Holdings to Issue 10M Ordinary Shrs Valued at $15M to Purchase CK Health >EUDA
EUDA Health Expands Into Direct Selling Holistic Wellness Products With Acquisition Of CK Health >EUDA
EUDA Health Expands Into Direct Selling Holistic Wellness Products With Acquisition Of CK Health >EUDA
Euda Health Adjusts Legal Fees, Issues Shares to Counsel
Euda Health Holdings Statement Lacks Content
EUDA Health Successfully Regains Compliance With Nasdaq Listing Requirements
EUDA Health Successfully Regains Compliance With Nasdaq Listing Requirements
EUDA Health Holdings Limited Has Regained Compliance With Nasdaq Capital Market's Continued...
EUDA Health Holdings Limited Has Received Nasdaq Notification Regarding Minimum Market Value Deficiency
Singapore., Jan. 16, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" and the "Company") received a written notice (the "MVLS Notice") from Listing Qualifications Department of The Nasdaq Stock Market
EUDA Health Holdings Second Quarter 2023 Earnings: US$0.28 Loss per Share (Vs US$1.86 Loss in 2Q 2022)
Today, EUDA Health Is On The Rise
EUDA Health Holdings Limited (NASDAQ: EUDA) shares are ascending today, defying the absence of any noteworthy developments emanating from the digital health platform. At the last check in the early session, EUDA Health's stock exhibited an impressive surge of 13.85%, commanding a unit price of $0.91. It is discernible that there are no recent press ...
U.S. Shares Lower at Close of Trade; Dow Jones Industrial Average Down 0.75%
Bioline Rx, Clever Leaves Among Healthcare Movers
Singaporean digital health platform EUDA Health merges with TheoreMRX
(Medical News October 7, 2023) Singaporean digital health platform EUDA Health announced that it has signed a letter of intent to merge with TheoreMRX on October 4, 2023. TheoreMRX is a privately held company headquartered in the United States that focuses on serving patients with cancer and women's health problems, and developing new treatments with safe drug use, low toxicity, and high potential for multiple drug use. Dr. Chen Weiwen, founder and CEO of EUDA, said, “TheoreMRX has sufficient funding channels, and the drug pipeline covers treatment areas where market demand is strong but not yet met
Analysis
Price Target
No Data
